Form 4: Arcturus Therapeutics Executive Granted 60,000 Stock Options

Arcturus Therapeutics' Chief Scientific Officer and COO, Pad Chivukula, was granted 60,000 stock options on December 16, 2024.

Summary

• Pad Chivukula, the Chief Scientific Officer and COO of Arcturus Therapeutics Holdings Inc., was granted 60,000 employee stock options on December 16, 2024.
• The options have an exercise price of $16.24 per share.
• These options vest 25% on December 16, 2025, and the remaining 75% vest in equal monthly increments over the following 36 months.
• The options expire on December 16, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives.
• The vesting schedule of 25% after one year and the remainder over the next three years is typical for executive stock options.
• The exercise price of $16.24 is specific to Arcturus Therapeutics and its current stock valuation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity compensation, executive compensation, Arcturus Therapeutics, Pad Chivukula, vesting, biotechnology